Safety, tolerability and pharmacodynamic results of a first-in-human study with the new antiplatelet agent ACT017 for the treatment of the acute phase of ischemic stroke
Christine Voors-Pette1, Peter Dogterom1, Laurie Jullien2, Martine Jandrot-Perrus3, and Gilles Avenard2
1QPS Netherlands, Groningen, The Netherlands, 2Acticor Biotech SAS, Paris, France, 3UMR_S1148 Inserm University Paris Diderot, Bichat Hospital, Paris, France